Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. Thank you for joining us and welcome to the Arcus Biosciences first quarter 2026 business updates and financial results. After today's prepared remarks, we will host a question and answer session. Please limit yourself to one question and one follow up. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Holly Kolke. VP of Corporate Affairs. Holly, please go ahead. Good afternoon, and thank you for joining us on today's conference call to discuss Arcasys' first quarter 2026 financial results and pipeline updates. I'd like to remind you that on this call, management will make forward-looking statements, including statements about our development strategies and our expectations regarding the advantages and opportunities afforded by our investigational products, our clinical development milestones and timelines, our projected cash runway, and our financial outlook. All statements other than historical facts reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent quarterly report on Form 10-Q that has been filed with the SEC. For today's call, please refer to our latest corporate presentation posted in the investor section of our website. This afternoon, you will hear from our CEO, Terry Rosen, Chief Medical Officer, Richard Marcus, President, Juan Jaen, and CFO, Bob Guelph. With that, I'd like to turn the call over to Terry. Thanks very much, Holly, and thanks, everyone, for joining us this afternoon. We're starting a new era for Arcus with full ownership of our lead program ...